C
Cristiana Lupi
Researcher at University of Pisa
Publications - 36
Citations - 3451
Cristiana Lupi is an academic researcher from University of Pisa. The author has contributed to research in topics: KRAS & Bevacizumab. The author has an hindex of 19, co-authored 36 publications receiving 3009 citations.
Papers
More filters
Journal ArticleDOI
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini,Fotios Loupakis,Carlotta Antoniotti,Cristiana Lupi,Elisa Sensi,Sara Lonardi,Silvia Mezi,Gianluca Tomasello,Monica Ronzoni,Alberto Zaniboni,Giuseppe Tonini,Chiara Carlomagno,Giacomo Allegrini,Silvana Chiara,Mauro D'Amico,Cristina Granetto,Marina Cazzaniga,Luca Boni,Gabriella Fontanini,Alfredo Falcone +19 more
TL;DR: An updated analysis of the TRIBE study aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups, and assessed the secondary endpoint of overall survival in the main cohort.
Journal ArticleDOI
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Rossella Elisei,Clara Ugolini,David Viola,Cristiana Lupi,Agnese Biagini,Riccardo Giannini,Cristina Romei,Paolo Miccoli,Aldo Pinchera,Fulvio Basolo +9 more
TL;DR: The BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features in PTC patients, who were not only at a higher risk not to be cured but also for death.
Journal ArticleDOI
Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma
Cristiana Lupi,Riccardo Giannini,Clara Ugolini,Agnese Proietti,Piero Berti,Michele Minuto,Gabriele Materazzi,Rossella Elisei,Massimo Santoro,Paolo Miccoli,Fulvio Basolo +10 more
TL;DR: The data suggest that BRAF V600E mutation is associated with high-risk PTC and in particular in follicular variant with invasive tumor growth.
Journal ArticleDOI
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
Gianluca Masi,Fotios Loupakis,Lisa Salvatore,Lorenzo Fornaro,Chiara Cremolini,Samanta Cupini,A. Ciarlo,Francesca Del Monte,Enrico Cortesi,Domenico Amoroso,Cristina Granetto,Gabriella Fontanini,Elisa Sensi,Cristiana Lupi,Michele Andreuccetti,Alfredo Falcone +15 more
TL;DR: The primary endpoint was progression-free survival at 10 months from study entry in the intention-to-treat population, and treatment achieved promising results in terms of PFS.
Journal ArticleDOI
The BRAF V600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study
Rossella Elisei,David Viola,Liborio Torregrossa,Riccardo Giannini,Cristina Romei,Clara Ugolini,Eleonora Molinaro,Laura Agate,Agnese Biagini,Cristiana Lupi,Laura Valerio,Gabriele Materazzi,Paolo Miccoli,Paolo Piaggi,Aldo Pinchera,Paolo Vitti,Fulvio Basolo +16 more
TL;DR: The BRAF(V600E) mutation was demonstrated to be a poor prognostic factor for the persistence of the disease independent from other clinical-pathological features in low-risk intrathyroid PTC patients, and could be useful to identify those who require less or more aggressive treatments.